Grace Therapeutics Management
Management criteria checks 0/4
Grace Therapeutics' CEO is Prashant Kohli, appointed in Apr 2023, has a tenure of 1.58 years. total yearly compensation is $987.63K, comprised of 40.5% salary and 59.5% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $70.05K. The average tenure of the management team and the board of directors is 1.5 years and 1.4 years respectively.
Key information
Prashant Kohli
Chief executive officer
US$987.6k
Total compensation
CEO salary percentage | 40.5% |
CEO tenure | 1.6yrs |
CEO ownership | 0.2% |
Management average tenure | 1.5yrs |
Board average tenure | 1.4yrs |
Recent management updates
Recent updates
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Sep 02We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
Apr 20Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Nov 14We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
May 10Acasti Pharma GAAP EPS of -$0.10
Aug 11Acasti inks deal for Grace Therapeutics, shares surge
May 07Acasti Pharma issues clarification on trading activity
Dec 23Acasti Pharma EPS in-line
Nov 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$12m |
Jun 30 2024 | n/a | n/a | -US$11m |
Mar 31 2024 | US$988k | US$400k | -US$13m |
Dec 31 2023 | n/a | n/a | -US$39m |
Sep 30 2023 | n/a | n/a | -US$40m |
Jun 30 2023 | n/a | n/a | -US$42m |
Mar 31 2023 | US$512k | US$379k | -US$42m |
Dec 31 2022 | n/a | n/a | -US$17m |
Sep 30 2022 | n/a | n/a | -US$17m |
Jun 30 2022 | n/a | n/a | -US$11m |
Mar 31 2022 | US$655k | US$141k | -US$10m |
Compensation vs Market: Prashant's total compensation ($USD987.63K) is above average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Prashant's compensation has increased whilst the company is unprofitable.
CEO
Prashant Kohli (52 yo)
1.6yrs
Tenure
US$987,630
Compensation
Mr. Prashant Kohli was Vice President of Commercial Operations at Grace Therapeutics, Inc. He served as Chief Commercial Officer at Acasti Pharma Inc. since 2022 until April 04, 2023, and serves as its Chi...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 1.6yrs | US$987.63k | 0.21% $ 70.0k | |
VP of Program Management | 1.5yrs | US$405.75k | 0.11% $ 36.5k | |
VP of Clinical Operations | 1.5yrs | US$411.30k | 0% $ 0 | |
VP of Finance and Principal Financial & Accounting Officer | less than a year | no data | no data | |
Member of Scientific Advisory Board & Chief Medical Officer | 1.5yrs | no data | no data |
1.5yrs
Average Tenure
52yo
Average Age
Experienced Management: GRCE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 1.1yrs | US$987.63k | 0.21% $ 70.0k | |
Member of Scientific Advisory Board & Chief Medical Officer | 2.5yrs | no data | no data | |
Independent Director | 1.1yrs | US$53.00k | 0.37% $ 124.3k | |
Independent Director | 1.1yrs | US$57.50k | 0% $ 0 | |
Independent Chairman | 3.3yrs | US$127.43k | 15.92% $ 5.3m | |
Director | 1.1yrs | US$44.90k | 3.65% $ 1.2m | |
Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
Member of Scientific Advisory Board | 1.4yrs | no data | no data |
1.4yrs
Average Tenure
56yo
Average Age
Experienced Board: GRCE's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.